Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CAR-T cell therapies - TxCell

Drug Profile

Research programme: CAR-T cell therapies - TxCell

Alternative Names: CAR engineered CD4+ Treg cells - TxCell; CD4+ CD25+ CD45RA+ Tregs; CD45RA+ Tregs; ENTrIA; ENTX-BP; ENTX-LN

Latest Information Update: 24 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ospedale San Raffaele; TxCell; University of Lubeck; Weizmann Institute of Science
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bullous pemphigoid
  • Research Inflammatory bowel diseases; Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 24 Oct 2018 Early research in Inflammatory bowel disease in France (Parenteral)
  • 24 Oct 2018 Early research in Rheumatoid arthritis in France (Parenteral)
  • 01 Oct 2018 TxCell has been acquired by Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top